Bicocca Open Archive

Logo unimib boa
FALANGA, ANNA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.289
AS - Asia 4.436
EU - Europa 3.486
SA - Sud America 962
AF - Africa 88
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 2
Totale 17.270
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.053
SG - Singapore 1.877
HK - Hong Kong 1.329
RU - Federazione Russa 994
BR - Brasile 788
CN - Cina 653
IE - Irlanda 562
SE - Svezia 525
IT - Italia 496
DE - Germania 441
VN - Vietnam 285
CA - Canada 169
GB - Regno Unito 111
AT - Austria 83
UA - Ucraina 72
AR - Argentina 70
ID - Indonesia 61
IN - India 50
MX - Messico 50
BD - Bangladesh 44
FR - Francia 35
NL - Olanda 35
ZA - Sudafrica 33
EC - Ecuador 30
FI - Finlandia 27
JP - Giappone 24
PL - Polonia 23
ES - Italia 21
IQ - Iraq 18
MA - Marocco 17
CO - Colombia 16
RO - Romania 16
CL - Cile 15
TR - Turchia 15
DK - Danimarca 12
KR - Corea 12
PE - Perù 12
PY - Paraguay 12
TN - Tunisia 10
VE - Venezuela 10
SA - Arabia Saudita 9
CH - Svizzera 8
UY - Uruguay 7
UZ - Uzbekistan 7
AE - Emirati Arabi Uniti 6
IL - Israele 6
MU - Mauritius 6
AU - Australia 5
EG - Egitto 5
KZ - Kazakistan 5
DO - Repubblica Dominicana 4
ET - Etiopia 4
GR - Grecia 4
JO - Giordania 4
OM - Oman 4
PK - Pakistan 4
CR - Costa Rica 3
IR - Iran 3
KE - Kenya 3
MY - Malesia 3
NP - Nepal 3
PA - Panama 3
PH - Filippine 3
PT - Portogallo 3
AL - Albania 2
BA - Bosnia-Erzegovina 2
BG - Bulgaria 2
BO - Bolivia 2
CZ - Repubblica Ceca 2
DZ - Algeria 2
GA - Gabon 2
HN - Honduras 2
JM - Giamaica 2
KH - Cambogia 2
LT - Lituania 2
NZ - Nuova Zelanda 2
RS - Serbia 2
SN - Senegal 2
TH - Thailandia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AM - Armenia 1
AO - Angola 1
AZ - Azerbaigian 1
BE - Belgio 1
BH - Bahrain 1
BW - Botswana 1
BY - Bielorussia 1
CI - Costa d'Avorio 1
EE - Estonia 1
GE - Georgia 1
GN - Guinea 1
GT - Guatemala 1
KG - Kirghizistan 1
LB - Libano 1
LK - Sri Lanka 1
LV - Lettonia 1
NO - Norvegia 1
SK - Slovacchia (Repubblica Slovacca) 1
SV - El Salvador 1
TT - Trinidad e Tobago 1
Totale 17.269
Salva come PNG Salva come JPEG
Città #
Hong Kong 1.324
Singapore 1.030
Ann Arbor 980
Fairfield 840
Ashburn 576
Dublin 558
Woodbridge 412
Wilmington 372
Chandler 368
Houston 359
New York 316
Frankfurt am Main 308
Princeton 308
Dallas 305
Cambridge 281
Seattle 261
Santa Clara 198
Beijing 155
Altamura 140
Lawrence 140
Jacksonville 139
Los Angeles 113
Chicago 104
Milan 104
Ho Chi Minh City 93
Moscow 85
Ottawa 80
San Diego 80
São Paulo 74
Hanoi 62
The Dalles 53
Toronto 50
Nuremberg 49
Buffalo 48
Andover 46
Vienna 46
Jakarta 39
Council Bluffs 37
Falls Church 32
Hefei 31
Shanghai 31
London 28
Salt Lake City 28
Rio de Janeiro 26
Redmond 24
Nanjing 23
Dearborn 22
Guangzhou 22
Dong Ket 20
Tokyo 20
Brasília 19
Warsaw 18
Norwalk 17
Phoenix 17
Orem 16
Brooklyn 15
Tampa 15
Florence 14
Helsinki 14
Atlanta 13
Elk Grove Village 13
Poplar 13
Campinas 12
Columbus 12
Montreal 12
Belo Horizonte 11
Chengdu 11
Curitiba 11
Dhaka 11
Jinan 11
Rome 11
Seoul 11
Wuhan 11
Ankara 10
Boardman 10
Denver 10
Fuzhou 10
Hangzhou 10
Johannesburg 10
Lancaster 10
Quito 10
Charlotte 9
Fara Gera d'Adda 9
Guayaquil 9
Porto Alegre 9
Sterling 9
Amsterdam 8
Guarulhos 8
Lima 8
Salvador 8
Sorocaba 8
Baghdad 7
Boston 7
Cape Town 7
Changsha 7
Haiphong 7
Hải Dương 7
Lappeenranta 7
Medellín 7
Mexico City 7
Totale 11.376
Salva come PNG Salva come JPEG
Nome #
A microphysiological early metastatic niche on a chip reveals how heterotypic cell interactions and inhibition of integrin subunit β3 impact breast cancer cell extravasation 283
D-dimer testing, with gender-specific cutoff levels, is of value to assess the individual risk of venous thromboembolic recurrence in non-elderly patients of both genders: a post hoc analysis of the DULCIS study 263
Treatment of venous thromboembolism with tinzaparin in oncological patients 247
FANCM c.5791C>T nonsense mutation (rs144567652) induces exon skipping, affects DNA repair activity and is a familial breast cancer risk factor 231
Fibrinolytic Proteins and Factor XIII as Predictors of Thrombotic and Hemorrhagic Complications in Hospitalized COVID-19 Patients 230
Long-term outcomes of patients with cerebral vein thrombosis: a multicenter study 216
Prevention of venous thromboembolism in patients with cancer: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET) 213
Thrombotic biomarkers for risk prediction of malignant disease recurrence in patients with early stage breast cancer 210
Management of bleeding in acquired hemophilia A: results from the European Acquired Haemophilia (EACH2) Registry 207
Tissue Plasminogen Activator Levels and Risk of Breast Cancer in a Case-Cohort Study on Italian Women: Results from the Moli-sani Study 201
Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2) 195
Trial of Rivaroxaban in AntiPhospholipid Syndrome (TRAPS): Two-year outcomes after the study closure 176
Post-operative heparin reduces early venous thrombotic complications after orthotopic paediatric liver transplantation 174
The use of direct oral anticoagulants for primary thromboprophylaxis in ambulatory cancer patients: Guidance from the SSC of the ISTH 173
Thrombocytopenia and Mortality Risk in Patients With Atrial Fibrillation: An Analysis From the START Registry 170
ISTH interim guidance on recognition and management of coagulopathy in COVID-19 163
Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update Summary 161
Activated prothrombin complex concentrate (FEIBA ® ) in acquired haemophilia A: a large multicentre Italian study – the FAIR Registry 161
Proceedings of the Second “International Conference on Thrombosis and Hemostasis Issues in Cancer”. September 19-21, 2003. Bergamo, Italy 159
Clozapine-induced anemia: A case-report 158
Venous thromboembolism and cancer: Guidelines of the Italian Association of Medical Oncology (AIOM) 156
Hemostatic biomarkers in occult cancer and cancer risk prediction 155
DOACs and “newer” hemophilia therapies in COVID-19: Reply 148
Anticoagulation in thrombocytopenic patients with hematological malignancy: A multinational clinical vignette-based experiment 146
Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update 144
Laboratory haemostasis monitoring in COVID-19 143
Cancer associated thrombosis in everyday practice: perspectives from GARFIELD-VTE 143
Fundamental Research in Oncology and Thrombosis 2 (FRONTLINE 2): A Follow-Up Survey 142
Grey zones on the use of new oral anticoagulants in atrial fibrillation. Expert opinion [Grey zones sull'uso dei nuovi anticoagulanti orali nella fibrillazione atriale. Opinioni degli esperti] 141
Addressing and proposing solutions for unmet clinical needs in the management of myeloproliferative neoplasm-associated thrombosis: A consensus-based position paper 139
Thrombin generation predicts early recurrence in breast cancer patients 139
Incidence of thrombotic complications in patients with haematological malignancies with central venous catheters: A prospective multicentre study 138
D-dimer to guide the duration of anticoagulation in patients with venous thromboembolism: a management study 137
Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research 136
COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review 134
Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera 134
Platelet cut-off for anticoagulant therapy in thrombocytopenic patients with blood cancer and venous thromboembolism: an expert consensus 130
Pathogenesis and management of the bleeding diathesis in acute promyelocytic leukaemia 129
Combined use of antifibrinolytics and activated prothrombin complex concentrate (aPCC) is not related to thromboembolic events in patients with acquired haemophilia A: data from FAIR Registry 129
Anticoagulation resumption after intracranial hemorrhage in patients treated with VKA and DOACs 127
Preliminary study to identify cancer patients at high risk of venous thrombosis following major surgery 126
Managing Anti-Platelet Therapy in Thrombocytopaenic Patients with Haematological Malignancy: A Multinational Clinical Vignette-Based Experiment 126
Vitamin K-Dependent Procoagulant in Cancer Cells: A Potential Target for the Antimetastatic Effect of Warfarin? 125
Unbalanced plasma control of TxA2 and PGI2 synthesis in Vitamin E deficient rats 125
Prospective Assessment of Clinical Risk Factors and Biomarkers of Hypercoagulability for the Identification of Patients with Lung Adenocarcinoma at Risk for Cancer-Associated Thrombosis: The Observational ROADMAP-CAT Study 125
Low levels of ADAMTS-13 with high anti-ADAMTS-13 antibodies during remission of immune-mediated thrombotic thrombocytopenic purpura highly predict for disease relapse: A multi-institutional study 125
THE HYPERCOAGULABLE STATE IN CANCER-PATIENTS - EVIDENCE FOR IMPAIRED THROMBIN INHIBITIONS 124
Guidance for the Management of Patients with Vascular Disease or Cardiovascular Risk Factors and COVID-19: Position Paper from VAS-European Independent Foundation in Angiology/Vascular Medicine 123
RECOMBINANT VERSUS HIGH-SENSITIVITY CONVENTIONAL THROMBOPLASTIN - A RANDOMIZED CLINICAL-STUDY IN PATIENTS ON ORAL ANTICOAGULATION 123
Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update 2014 122
Thrombophilic status may predict prognosis in patients with metastatic BRAFV600-mutated melanoma who are receiving BRAF inhibitors 121
The impact of all-trans-retinoic acid on the coagulopathy of acute promyelocytic leukemia 121
Procoagulant activity of mouse transformed cells: Different expression in freshly isolated or cultured cells 121
Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 119
A Multidisciplinary Approach on the Perioperative Antithrombotic Management of Patients With Coronary Stents Undergoing Surgery: Surgery After Stenting 2 119
Procoagulant mechanisms in tumour cells 118
V. Plasmaferesi terapeutica 118
Pathophysiology 1. Mechanisms of Thrombosis in Cancer Patients 117
Molecular basis for the relationship between thrombosis and cancer 116
Molecular biomarkers of thrombosis in myeloproliferative neoplasms 115
Association of plasma Protein C and CCL18 levels with neurodegenerative measures in Multiple Sclerosis patients 114
The mechanisms of cancer-associated thrombosis 113
The Italian START-Register on anticoagulation with focus on atrial fibrillation 113
Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results 113
Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome 113
The effect of very-low-dose warfarin on markers of hypercoagulation in metastatic breast cancer: Results from a randomized trial 112
Antithrombotic medication in cancer-associated thrombocytopenia: Current evidence and knowledge gaps 112
Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding 112
Evaluation of nucleated red blood cell count by Sysmex XE-2100 in patients with thalassaemia or sickle cell anaemia and in neonates 111
Thrombosis in myeloproliferative disorders: pathogenetic facts and speculation 110
The prevention and management of asparaginase-related venous thromboembolism in adults: Guidance from the SSC on Hemostasis and Malignancy of the ISTH 110
INEFFICACY OF INTRAVENOUS IMMUNOGLOBULIN IN PATIENTS WITH LOW-RISK THROMBOTIC THROMBOCYTOPENIC PURPURA/HEMOLYTIC-UREMIC SYNDROME 109
Management of Cancer-associated Disseminated Intravascular Coagulation: guidance from the SSC of the ISTH 108
Eradication of acquired hemophilia associated with indolent non-Hodgkin lymphoma by a disease specific treatment 108
Supranormal antithrombin III levels induced by concentrate administration are ineffective in quenching thrombin generation in acute promyelocytic leukemia 108
Hemostatic biomarkers in cancer progression 107
La coagulopatia indotta da trauma 107
Tissue Factor Expression on Platelet Surface during Preparation and Storage of Platelet Concentrates 107
Comparison between different D-Dimer cutoff values to assess the individual risk of recurrent venous thromboembolism: Analysis of results obtained in the DULCIS study 106
External validation of the DASH prediction rule: a retrospective cohort study 106
Risk of Venous Thromboembolism in Surgical Elderly Patients. 105
The predictive ability of bleeding risk stratification models in very old patients on vitamin K antagonist treatment for venous thromboembolism: Results of the prospective collaborative EPICA study 105
Recurrent venous thromboembolism in anticoagulated patients with cancer: management and short-term prognosis 105
Cancer and venous thromboembolism 105
Pathogenesis and treatment of thrombohemorrhagic diathesis in acute promyelocytic leukemia 105
Microparticles in tumor progression 104
Anticoagulation in Italian patients with venous thromboembolism and thrombophilic alterations: findings from START2 register study 103
Venous thromboembolism in the hematologic malignancies 102
Phospholipid-dependent procoagulant activity is highly expressed by circulating microparticles in patients with Essential Thrombocythemia 102
Type and dose of heparin in Covid-19: Reply 102
Proceedings of the Fifth International Conference on Thrombosis and Hemostasis Issues in Cancer, held in Stresa - Italy, April 23-25, 2010. Preface. 102
Meeting Report EuroG20 Meeting on Cancer-Associated Thrombosis (CAT) Bergamo, Italy 7 April 2016 99
Pharmacological inhibition of thromboxane-synthetase and platelet aggregation: Modulatory role of cyclooxygenase products. 99
The effect of Vitamin E or selenium on the oxidant-antioxidant balance in rats 99
Thrombosis in myeloproliferative neoplasms 98
Acute Promyelocytic Leukemia Coagulopathy 98
Several murine metastatizing tumors possess a cysteine proteinase with cancer procoagulant characteristics 98
Hypercoagulation screening as an innovative tool for risk assessment, early diagnosis and prognosis in cancer: The HYPERCAN study 98
Tromboxane synthetase inhibition results in increased platelet sensivity to prostacyclin. Thrombosis and Haemostasis 97
The International Conference on Thrombosis and Hemostasis Issues in Cancer (ICTHIC) at the Peak of Adolescence - 15 Years and Counting 97
Totale 13.432
Salva come PNG Salva come JPEG
Categoria #
all - tutte 78.490
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 78.490
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.449 0 0 0 0 0 214 287 296 173 162 187 130
2021/20221.551 160 169 178 92 61 74 93 102 68 97 110 347
2022/20232.055 369 575 190 140 96 407 7 91 97 17 41 25
2023/20241.482 27 52 20 18 227 407 262 46 245 20 5 153
2024/20254.342 306 732 200 167 356 74 291 96 417 613 332 758
2025/20264.034 656 607 830 950 927 64 0 0 0 0 0 0
Totale 17.949